[Vitamin K2 as a protector of bone health and beyond]

Clin Calcium. 2005 Apr;15(4):605-10.
[Article in Japanese]


Several lives of evidence indicate a protective effect of vitamin K against osteoporosis. Epidemiological studies showed that low vitamin K intake is associated with the increased risk of osteoporosis. Vitamin K2 (menatetrenone, MK-4) has been clinically used in the treatment of patients with osteoporosis in Japan, Korea and Thailand. Previous studies demonstrated the efficacy of vitamin K2 (45 mg/day) to prevent bone loss and reduce the rate of vertebral fractures, although a large, randomized intervention study is anticipated to provide more detailed evidence. Recently, vitamin K2 has been shown to reduce the progression of hepatocarcinoma. Moreover, it has been proposed that vitamin K may also have beneficial effects to prevent atherogenesis. The clarification of molecular mechanisms by which vitamin K2 exerts these salutary effects deserve further investigations.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Animals
  • Arteriosclerosis / prevention & control
  • Carcinoma, Hepatocellular / prevention & control
  • Dementia / prevention & control
  • Evidence-Based Medicine
  • Humans
  • Liver Neoplasms / prevention & control
  • Osteoporosis / prevention & control*
  • Randomized Controlled Trials as Topic
  • Spinal Fractures / etiology
  • Spinal Fractures / prevention & control
  • Vitamin K 2 / administration & dosage*


  • Vitamin K 2